Keywords
comorbidity
mortality
How to Cite
Abstract
Introduction: Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by chronic systemic inflammation. Causes of death in SLE have a bimodal pattern: during the first 5 years, infections and disease activity prevail, whereas beyond 5 years cardiovascular complications and accumulated organ damage are the main causes.
Objective: To determine causes of death in adult patients diagnosed with SLE admitted to the Department of internal Medicine of the National Hospital from January 2010 to December 2018.
Materials and methods: Retrospective, observational, descriptive, cross sectional study of adult patients admitted to the Department of internal Medicine and the Emergency Depart- ment of the National Hospital of Itauguá, from 2010 to 2018. Out of 585 patients with SLE admitted during this period, 63 died. 25 patients were included and 38 were excluded due to incomplete studies. SLE diagnosis was made according to SLiCC criteria. The variables analyzed were demographic, clinical, laboratory, causes of death, mortality. Data was analyzed with descriptive statistics. Frequencies and proportions were used for qualitative variables, means and standard deviation for continuous variables.
Results: 25 patients were included, 18 were women (72%) and 7 were men (28%). Mean
age was 30±15.5 (18-77). 40% (n=10) came from Central Department and 60% (n=15) were from the countryside. 70.8% of the patients had a disease duration between 2 and 5 years (n=18). 92% had been previously diagnosed with SLE. Regarding disease activity, patients presented with nephritis (76%), alveolar hemorrhage (12%), pneumonitis (4%), neurolupus (4%) and CNS vasculitis (4%). On the subject of infections, the following were found: nosocomial pneumonia (45%), community acquired pneumonia (8%), strongyloides hyperinfection (4%), disseminated cryptococcosis (4%). The main causes of death were infections (44%), followed by disease activity (36%) and causes not related to SLE (20%; severe mitral and aortic insufficiency, acute pulmonary edema secondary to chronic kidney disease as complication of lupus nephritis, hemorrhagic stroke). 100% received corticosteroids and 60% immunosuppressants.
Conclusion: Mortality was 10.8%, the main causes of death were infections followed by disease activity.
References
(1) Alba P. Morbimortalidad en el Lupus Eritematoso Sistémico. Rev Arg Reum.2015;26(1):7-8.
(2) Thomas G, Mancini J, Jourde-Chiche N, Sarlon G, Amoura Z, Harlé JR, et al. Mortality Associated With Systemic Lupus Erythematosus in France Assessed by Multiple Cause of Death Analysis. Arthritis y Rheumatol.2014;66(9):2503-11.
(3) Muñoz-Grajales C, Velásquez-Franco C, Márquez-Hernández J, Pinto-Peñaranda L. Hospitalización en Lupus Eritematoso Sistémico: Causas, Evolución, Complicaciones y Mortalidad. Ver Colomb Reumatol. 2014;21(2):65-9.
(4) Pons-Estel B, Catoggio L, Cardiel M, Cardiel MH, Soriano SR, Gentiletti S, et al Latinoamericano de Estudio del Lupus (GLADEL). The GLADEL Multinational Latin American Prospective Inception Cohort of 1,214 Patients with Systemic Lupus Erythematosus Ethnic and Disease Heterogeneit y among "Hispanics". Medicine. 2004;83:1-17.
(5). Jiménez-Alonso J, Hidalgo-tenorio C, Ruiz-irastorza G. Guías clínicas de enfermedades autoinmunes sistémicas. Soc Española Med Interna. 2011;1-70.
(6) Romaní F, Atencia F, Cuadra J, Canelo C. Lupus Eritematoso Sistémico, en un Paciente Varón: a propósito de un caso. Ann de la Fac Med. 2013;69(1):37-41.
(7) Urizar C. Troche N, Portillo C. frecuencia de complicaciones infecciosas en pacientes con lupus eritematoso sistémico y artritis reumatoide de la III cátedra de clínica médica (2014-2016). Rev. Parag. Reumatol. 2016;2(2):67-71.
(8) Ormea-villavicencio, A M-UG. Mortalidad en los Pacientes con Lupus Eritematoso Sistémico que Ingresaron a una Unidad de Cuidados Intensivos. Rev Soc Peru Med Interna.2009;22(4):145-50.
(9) Ayala A, Torres E, Montiel D. Causas de fiebre en pacientes adultos con lupus eritematoso sistémico. Rev. virtual Soc. Parag. Med. Int. 2017;4(1):35-45.
(10) Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during
a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore).2003;82(5):299-308.
(11) Wang Z, Wang Y, Zhu R, Tian X, Xu D, Wang Q, et al. Long Term Survival and Death Causes of Systemic Lupus Erythematosus in China. Medicine (Baltimore). 2015;94(17):1-9.
(12) Vargas-Marin, J, Moreira-Vasquez C, Delgado, k. causas de muerte en pacientes con lupus eritematoso sistémico (les) en el hospital México de 1989 a 2004. revista médica de Costa Rica y Centroamérica. 2010;(594)337-343.
(13) Rúa-Figueroa I, Erausquin C. Factores Asociados a la Mortalidad del lupus Eritematoso Sistémico. Semin fund Esp Reum. 2008;9(4):219-34.
(14) Mejía, F, Molina J, Uribe O, De la Cruz O, Zambrano F. Factores Pronósticos en la Mortalidad por Lupus Eritematoso Sistémico. Acta méd colomb. 1986;11(1):2-7.
(15) Petri M, Orbai AM, Alarcon G, Gordon G, Merrill JT, Fortin PR, et al. Derivation and Validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus. arthritis & rheumatism. 2012; 64(8):2677–2686.
(16) Garcia, R, Sermeño S. Mortalidad por Lupus eritematoso Sistémico en un Hospital del Salvador. Rev Arch Col Med. 2008;1(1):2-5.
(17) Costi L, Iwamoto H, Costa D, Neves D, Muniz-Caldas C. Mortalidade por Lúpus Eritematoso Sistêmico no Brasil: Avaliação das Causas de Acordo com o Banco de Dados de Saúde do Governo. Rev Bras Reumatol.2017;57(6):574–82. Available from: http://dx.doi.org/10.1016/j.rbr.2017.05.007
(18) Koh JH, Park EK, Lee HN, Kim Y, Kim GT, Suh YS et al. Clinical characteristics and survival of 413 patients with systemic lupus erythematosus in southeastern areas of South Korea: A multicenter retrospective cohort study. Int J Rheum Dis. 2019 Dec 4. doi:10.1111/1756-185X.13761.8.
(19) Anver H, Dubey S, Fox J. Changing trends in mortality in systemic lupus erythematosus? An analysis of SLE inpatient mortality at University Hospital Coventry and Warwickshire NHS Trust from 2007 to 2016. Rheumatology International 2019.https://doi.org/10.1007/s00296-019-04450-1
(20) Sharma A, Shamanna SB, Kumar S, Wanchu A, Bambery P, Singh S, et al. Causes of mortality among inpatients with systemic lupus erythematosus in a tertiary care hospital in North India over a 10-year period. Lupus. 2013;22(2):216-22.
(21) Pamuk ON, Akbay FG, Dönmez S, Akbay FG, Yilmaz N. The clinical manifestations and survival of systemic lupus erythematosus patients in Turkey: report from two centers. Lupus. 2013;22(13):1416-24.
(22) Enberg M, Kahn M, Goity C, Villalón MV, Zamorano J, Figueroa F. Infecciones en pacientes con lupus Eritematoso sistémico. Rev Méd Chile. 2009;137:1367-1374.
(23) Muñoz-Grajales C, Pinto Peñaranda L, Velásquez Franco C. et al. Complicaciones infecciosas en lupus eritematoso sistémico. Rev colomb reumatol. 2013;20(3):141-147.
(24) Puges M, Biscay P, Barnetche T, Truchetet ME, Richez C, Seneschal J, et al. Immunogenicity and impact on disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic literature review and meta-analysis. Rheumatology (Oxford). 2016;55(9):1664-72.
(25) Bosaeed M, Kumar D. Seasonal influenza vaccine in immunocom promised persons. Human vaccines & immunotherapeutics. 2018; 14(6):1311-1322.
(26) Tristano A. Criptococosis meníngea y lupus eritematoso sistémico: Reporte de un caso y revisión de la literatura. RevChil Infect. 2010; 27(2):155-159.
(27) Llagunes J, Mateo E, Peña J. Hiperinfeccion por Strongyloides stercoralis. Med Intensiva. 2010;34(5):353-356.
(28) Gräb J, Suárez I, van Gumpel E, Winter S, Schreiber F, Esser A, et al. Corticosteroids inhibit Mycobacterium tuberculosis – induced necrotic host cell death by abrogating mitochondrial membrane permeability transition. Nat Commun. 2019;10(1):688.
(29) Bharath G, Kumar P, Makkar N, Singla P, Soneja M, Biswas A, et al. Mortality in Systemic Lupus Erythematosus at a Teaching Hospital in India: A 5 Year Retrospective Study. J Fam Med Prim Care. 2019;8(7):2511-5.
(30) Zonana-Nacach A, Yañez P, Jiménez-Balderas FJ, Camargo Coronel A Disease activity, damage and survival in Mexican patients with acute severe systemic lupus erythematosus. Lupus. 2007;16(12):997-1000.